Evidence map›Paper›PMID 36482942›Full record

ArticleMolecular and clinical oncology2022

Combination chemotherapy of doxorubicin and ifosfamide with proton beam therapy for myoepithelial carcinoma originating in the paraspinal region: A case report and literature review.

Shunichi Toki, Toshihiko Nishisho, Ryo Miyagi, Yoshimi Bando, Mika Sakaki, Yusuke Demizu, Tomoaki Okimoto, Koichi Sairyo

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Molecular and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Very rare myoepithelial carcinoma occurred in the humerus: a case report.International journal of surgery case reports · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shunichi TokiDepartment of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan.
Toshihiko NishishoDepartment of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan.
Ryo MiyagiDepartment of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan.
Yoshimi BandoDivision of Pathology, Tokushima University Hospital, Tokushima 770-8503, Japan.
Mika SakakiDivision of Pathology, Tokushima University Hospital, Tokushima 770-8503, Japan.
Yusuke DemizuDepartment of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, Kobe, Hyogo 650-0047, Japan.
Tomoaki OkimotoDepartment of Radiology, Hyogo Ion Beam Medical Center, Hyogo 679-5165, Japan.
Koichi SairyoDepartment of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan.
Tokushima University · JPHyogo Ion Beam Medical Center · JPTokushima University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soft tissue myoepithelial carcinoma (MEC) is an extremely rare mesenchymal tumor that has a poor prognosis unless complete surgical resection is achieved. The present study reported a case of a 38-year-old woman with a tumor in the left paraspinal region at L2 to L3 with vertebral destruction. MEC was diagnosed based on molecular pathological examination of a biopsy specimen. Because curative surgery was expected to be difficult, a combination of chemotherapy with doxorubicin and ifosfamide and proton beam therapy as local therapy was performed, resulting in long-term survival for at least 7.8 years. To the best of our knowledge, this is the first case of soft tissue MEC for which classical cytotoxic chemotherapy and proton beam therapy were effective. Although surgical resection with negative margins is the mainstay of treatment for MEC, adequate doxorubicin-based systemic therapy and high-dose radiation therapy may be a feasible alternative in patients with unresectable or advanced MEC. Future studies on the relationship between molecular pathological features, including biomarkers, and the selection of therapeutic agents are warranted.

Indexed as

doxorubicinEWSR1ifosfamideINI-1myoepithelial carcinomaproton beam therapy

Identifiers

PMID36482942
PMCPMC9716338
OpenAlexW4308249751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.